Empowering End-to-End Research and Development of Innovative Biologics

At PharMolix, we combine drug discovery expertise with multimodal biomedical foundation models and intelligent agents to advance our proprietary pipeline. Our ChatDD platform enables researchers to work with AI agents to understand disease biology and develop drug candidates. Expert judgment and experimental feedback guide each round of molecular design and optimization. Our programs focus on autoimmune diseases and cancer, with the goal of developing differentiated therapies that address unmet clinical needs.

In our first proprietary program, we nominated a preclinical candidate (PCC) with first-in-class potential just seven months after initiation of the project. Through an iterative design–test–learn process, experimental results guide each new round of molecular design and optimization. This approach helps us advance our drug programs while continuously refining our AI platform.